PF-08046049

Phase 1Small molecule

Pfizer

PF-08046049 is one of 80 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous MelanomaTerminated

MelanomaActive, not recruiting

Cutaneous MelanomaPhase 1

Terminated

MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Rhuph20

Bristol-Myers Squibb

Phase 3

1 2

Deltavit

HHyundai Pharmaceutical Co., LTD.

Epacadostat

1 4

Adjuvant Therapy

FFudan University

Phase 3

1 5

Tumor Necrosis Factor

NNational Cancer Institute (NCI)

Phase 3

1 6

Relatlimab+nivolumab

Bristol-Myers Squibb

Phase 3

2 7

Anti-PD1

Pfizer

Phase 3

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Melanoma1 trial

A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05571839·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PF-08046049. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-08046049 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-08046049. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-08046049

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News